ストックスクリーナーアプリを入手
1.74
0.57%
-0.01
プレマーケット:
1.70
-0.04
-2.30%
前日終値:
$1.75
開ける：
$1.75
24時間の取引高:
1.31M
Relative Volume:
0.85
時価総額：
$116.56M
収益：
-
当期純損益:
$-122.44M
株価収益率:
-0.772
EPS:
-2.254
ネットキャッシュフロー:
$-103.79M
1週間 パフォーマンス:
+8.75%
1か月 パフォーマンス:
+1.16%
6か月 パフォーマンス:
-77.69%
1年 パフォーマンス:
-46.46%
1日の値動き範囲:
$1.72
$1.79
1週間の範囲:
$1.57
$1.82
52週間の値動き範囲:
$1.40
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
名前
Engene Therapeutics Inc
セクター
電話
(514) 332-4888
住所
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
1.74 | 118.57M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | WBB Securities | Buy |
| 2026-01-30 | 開始されました | Jefferies | Buy |
| 2025-11-11 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | 開始されました | Piper Sandler | Overweight |
| 2025-02-14 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-27 | 開始されました | Raymond James | Outperform |
| 2024-11-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-08-28 | 開始されました | Oppenheimer | Outperform |
| 2024-04-22 | 開始されました | Wells Fargo | Overweight |
| 2024-04-15 | 開始されました | Guggenheim | Buy |
| 2024-03-28 | 開始されました | UBS | Buy |
| 2024-03-08 | 開始されました | Morgan Stanley | Overweight |
| 2024-02-20 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Engene Therapeutics Inc (ENGN) 最新ニュース
enGene Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
EnGene Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 - marketscreener.com
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
enGene Therapeutics Inc. (ENGNW) Q2 2026 Quarterly Report: Financial Highlights, Risk Factors, and Forward-Looking Statements - Minichart
enGene Therapeutics (ENGN) Q2 2026 earnings summary - Quartr
enGene Therapeutics reports Q2 2026 financial results - grafa.com
enGene Reports Q2 2026 Results: 50% Workforce Reduction, BLA Initiation for Detalimogene in 2H 2026, $285M Cash Position, and NMIBC Clinical Updates 12 – Minichart - Minichart
enGene Restructures, Cuts Workforce to Advance Bladder Therapy - TipRanks
enGene Therapeutics Inc. Q3 2026: Net loss $30.2M, EPS ($0.43) — 10-Q Summary - TradingView
ENGN: Net loss increased, workforce halved, and liquidity remains strong for at least 12 months - TradingView
enGene Therapeutics (ENGN) posts $60M loss, cuts workforce by 50% - Stock Titan
enGene (NASDAQ: ENGN) slashes staff 50% as it advances detalimogene BLA - Stock Titan
Genetic medicines company enGene cuts half its staff to focus on FDA filing - Stock Titan
enGene Therapeutics Inc. (ENGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why is enGene Therapeutics stock falling Friday? - MSN
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
ENGN Q2'26 Earnings: EPS estimate is (0.47) USD - TradingView
Number of shareholders of enGene Therapeutics Inc. – NASDAQ:ENGN - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against enGene Therapeutics Inc. (ENGN) And Encourages Shareholders to Reach Out - ACCESS Newswire
enGene Holdings Shareholders Approve Board and Auditor Slate - TipRanks
Shareholders at enGene (ENGN) 2026 meeting back directors and auditor - Stock Titan
Number of shareholders of enGene Therapeutics Inc. – BOATS:ENGN - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against enGene Therapeutics Inc. (ENGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
ENGN: Directors elected through 2029 and auditor reappointed, with all proposals approved - TradingView
enGene Therapeutics Inc. (ENGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-08 | enGene Therapeutics Inc. (ENGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ENGN | Press Release - Stockhouse
enGene Therapeutics: The Market Overreacted To The Latest Trial Results (NASDAQ:ENGN) - Seeking Alpha
Daily Brief Health Care: Laurus Labs, BeOne Medicines, enGene Therapeutics, Hansoh Pharmaceutical, Parabilis Medicines and more - Smartkarma
Daily Brief United States: SpaceX, Rocket Lab USA , Servicenow Inc, Vanguard Short-Term Corporate, Parabilis Medicines, enGene Therapeutics, Crude Oil, Forbright, ERock and more - Smartkarma
Bronstein, Gewirtz & Grossman, LLC Is Investigating enGene Therap - The National Law Review
2026-06-07 | Bronstein, Gewirtz & Grossman, LLC Is Investigating enGene Therapeutics Inc. (ENGN) And Encourages Investors to Connect | NDAQ:ENGN | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages enGene Therapeutics - The National Law Review
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Encourages enGene Therapeutics Inc. (ENGN) Stockholders to Inquire about Securities Investigation | NDAQ:ENGN | Press Release - Stockhouse
ENGN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
2026-06-03 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against enGene Therapeutics Inc. (ENGN) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ENGN | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against enGene Therapeutics Inc. (ENGN) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages enGene Therapeutics Inc. (ENGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc.ENGN - ACCESS Newswire
enGene Therapeutics faces securities fraud probe after trial results cause 80% stock plunge - Pluang
EnGene bladder cancer data shows promise, but durability questions remain - MSN
enGene Therapeutics Inc. Stock Portfolio - Intellectia AI
Dow Dips 350 Points; US Foods Posts Downbeat Earnings - Sahm
Law firm probes enGene Therapeutics over stock plunge after disappointing cancer trial results - Pluang
Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc.ENGN - FinancialContent
EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
enGene (ENGN) filing: Cormorant and Bihua Chen report 0 shares - Stock Titan
BML Investment Partners reports 9.95% stake in enGene Holdings (ENGN) - Stock Titan
ENGN SEC FilingsenGene Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
UBS Adjusts EnGene Price Target to $2 From $9, Maintains Neutral Rating - Moomoo
BML Investment Partners discloses 7.8% stake in enGene (ENGN) on 05/08/2026 - Stock Titan
Engene Therapeutics Inc (ENGN) 財務データ
収益
当期純利益
現金流量
EPS
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):